KLK3 and prostate carcinoma: The release of a serological marker for monitoring advanced tumors, such as LDH (lactate dehydrogenase for melanoma) [54] or PSA (prostate-specific antigen for prostate cancer) [55], may be different between primary and metastatic sites or between metastatic sites [56].